Concurrent radiochemotherapy for patients with stage III non-small-cell lung cancer (NSCLC): Long-term results of a phase II study

International Journal of Radiation Oncology Biology Physics

Volumn 42, Issue 5, 1998, Pages 1091-1096

  Jeremic, Branislav ^a   Shibamoto, Yuta ^b   Milicic, Biljana ^a   Nikolic, Nebojsa ^a   Dagovic, Aleksandar ^a   Milisavljevic, Slobodan ^a  

^a University Hospital   (Serbia)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Nonsmall cell lung cancer; Radiation therapy

Indexed keywords

CARBOPLATIN; ETOPOSIDE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION SICKNESS;

EID: 0032411884     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00283-1     Document Type: Article

References (33)

1. Choi N.C.H., Doucette J.A. Improved survival of patients with unresectable non-small cell bronchogenic carcinoma by an innovated high-dose en bloc radiotherapeutic approach. Cancer. 48:1981;101-109.
2. Perez C., Stanley K., Grundy G., et al. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Cancer. 50:1982;1091-1099.
3. Petrovich Z., Stanley K., Cox J., et al. Radiotherapy and the management of locally advanced lung cancer of all cell types. Final report of randomized trial. Cancer. 48:1981;1335-1340.
4. Albain K.S., Rusch V.W., Crowley J.J., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer : Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 13:1995;1880-1892.
5. Burkes R.L., Ginsberg R.J., Sheperd F.A., et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer results of the Toronto phase II trial . J Clin Oncol. 10:1992;580-586.
6. Choi N.C., Carey R.W., Daly W., et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol. 15:1997;712-722.
7. Sugarbaker D.J., Herndon J., Kohman L.J., et al. Results of cancer and leukemia Group B protocol 8935 A multi-institutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer . J Thorac Cardiovasc Surg. 109:1995;473-485.
8. Dillman R.O., Seagren S.L., Herndon J., et al. Randomized trial of induction chemotherapy plus radiation therapy vs RT alone in stage III non-small cell lung cancer (NSCLC) Five year follow up of CALGB 84-33 . (Abstr.) Proc Am Soc Clin Oncol. 12:1993;329.
9. LeChevalier T., Arriagada R., Lacombe-Terrier M.-J., et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma. (Letter) J Natl Cancer Inst. 84:1992;58.
10. Sause W.T., Scott C., Taylor S., et al. Radiation Therapy Oncology Group 88-08 and Eastern Cooperative Oncology Group 4588 Preliminary resulrs of a phase III trial in regionally advanced, unresectable nonsmall cell lung cancer . J Natl Cancer Inst. 87:1995;198-205.
11. Sause W.T., Scott C., Taylor S., et al. RTOG 8808 ECOG 4588. Preliminary analysis of a phase III trial in regionally advanced unresectable non-small cell lung cancer with minimum three year follow-up. (Abstr.) Proc Am Soc Ther Radiol Oncol. 37:1995;109.
12. Byhardt R.W., Scott C.B., Ettinger D.S., et al. Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90-15. Cancer. 75:1995;2337-2344.
13. Komaki R., Scott C., Ettinger D., et al. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer Radiation Therapy Oncology Group (RTOG) 92-04 . Int J Radiat Oncol Biol Phys. 38:1997;149-155.
14. Lau D.H.M., Ryu J.K., Gandara D.R., et al. Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma A pilot study . Int J Radiat Oncol Biol Phys. 38:1997;157-161.
15. Lee J.S., Scott C., Komaki R., et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer Radiation Therapy Oncology Group protocol 91-06 . J Clin Oncol. 14:1996;1055-1064.
16. Jeremic B., Shibamoto Y., Acimovic Lj, et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol. 13:1995;452-458.
17. Jeremic B., Shibamoto Y., Acimovic Lj, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-samll-cell lung cancer A randomized study . J Clin Oncol. 14:1996;1065-1070.
18. Schaake-Konig C., van der Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 326:1992;524-530.
19. Cox J.D., Azarnia N., Byhardt R.W., et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with ≥ 69.6 Gy in favorable patients with Radiation Therapy Oncology Group Stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 8:1990;1453-1555.
20. Drewinko B., Green C., Loo T.L. Combination chemotherapy in vitro with cisdichlorodiammineplatinum (II). Cancer Treat Rep. 60:1979;1619-1625.
21. Schabel F.M., Trader M.W., Laster W.K. Cancer Treat Rep. 63:1979;1459-1473.
22. Pfeffer M.R., Teicher B.A., Holden S.A., et al. The interaction of cisplatin plus etoposide with radiation + hyperthermia. Int J Radiat Oncol Biol Phys. 19:1990;1439-1447.
23. Robinow J.S., Shaw E.G., Eagan R.T., et al. Results of combination chemotherapy and thoracic radiation therapy for unresectable non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 17:1989;1203-1210.
24. Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for the Treatment and Research of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-1346.
25. Jeremic B., Shibamoto Y. Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for stage III nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 34:1996;303-308.
26. Bardet E., Riviere A., Charloux A., et al. A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced non-small cell lung cancer final analysis . Int J Radiat Oncol Biol Phys. 38:1997;163-168.
27. Kelly K., Bunn P.A. Jr, Hazuka M., et al. A phase I-II trial of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation followed by carboplatin in patients with regionally inoperable nonsmall cell lung cancer. (Abstr.) Proc Am Soc Clin Oncol. 14:1995;377.
28. Kunitoh H., Watanabe K., Nagatomo A., et al. Concurrent daily carboplatin and accelerated hyperfractionated thoracic radiotherapy in locally advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 37:1997;103-109.
29. Murray N., Shah A., Osoba D., et al. Intensive weekly chemotherapy for the treatment of extensive-stage small-celllung cancer. J Clin Oncol. 9:1991;1632-1638.
30. Sculier J.P., Pasemans M., Bureau G., et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-celll lung cancer A phase III randomized study conducted by the European Lung Cancer Working Party . J Clin Oncol. 11:1993;1858-1864.
31. Furuse K., Fukuoka M., Takada Y., et al. A randomized phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with mitomycin (M), vindesine (V), and cisplatin (P) in unresectablw stage III non-small cell lung cancer (NSCLC) preliminary analysis . (Abstr.) Proc Am Soc Clin Oncol. 16:1997;459.
32. Graham M.V., Purdy J.A., Emami B., et al. Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 33:1995;993-1000.
33. Robertson JM, Ten Haken RK, Hazuka MB; et al. Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1079-1085.